Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical is positioned favorably because its core musculoskeletal franchise is compounding through share gains, rep recruitment, and robotic pull-through, with U.S. Spine growing 10% y/y for a third consecutive quarter and trauma up 30%+ y/y. Q1 delivered 11% organic revenue growth to $760 million, gross margin expanded to 69.2%, operating margin reached 25.2%, and adjusted EPS of $1.12 beat consensus by ~22%, underscoring strong execution and operating leverage. Management’s reiterated 2026 revenue guide of $3.18-3.22 billion, raised EPS outlook to $4.70-4.80, a debt-free balance sheet with $799 million in cash, and a growing Enabling Technologies pipeline support further margin expansion and durable long-term upside.

Globus Medical is facing a negative outlook because its core spine business is exposed to intensifying competition from larger device makers such as MDT, SYK, and ZBH, while staffing shortages, pricing pressure, and FX/macro headwinds could further constrain growth and profitability. The NuVasive and Nevro integrations add execution risk, and the text notes that Nevro sales were $83M in 1Q26, down 17% Q/Q, with adjusted EBITDA margin falling to 11.8% from 21.2% in 4Q25, underscoring near-term disruption. With bear-case assumptions calling for revenue growth slowing to the low-single digits and flat margins, product quality, recall exposure, and weaker-than-expected Enabling Technologies sales reinforce the cautious stance.